Example of The Lancet Infectious Diseases format
Recent searches

Example of The Lancet Infectious Diseases format Example of The Lancet Infectious Diseases format Example of The Lancet Infectious Diseases format Example of The Lancet Infectious Diseases format Example of The Lancet Infectious Diseases format Example of The Lancet Infectious Diseases format Example of The Lancet Infectious Diseases format Example of The Lancet Infectious Diseases format Example of The Lancet Infectious Diseases format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
Look Inside
Example of The Lancet Infectious Diseases format Example of The Lancet Infectious Diseases format Example of The Lancet Infectious Diseases format Example of The Lancet Infectious Diseases format Example of The Lancet Infectious Diseases format Example of The Lancet Infectious Diseases format Example of The Lancet Infectious Diseases format Example of The Lancet Infectious Diseases format Example of The Lancet Infectious Diseases format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
open access Open Access
recommended Recommended

The Lancet Infectious Diseases — Template for authors

Publisher: Elsevier
Categories Rank Trend in last 3 yrs
Infectious Diseases #4 of 288 -
journal-quality-icon Journal quality:
High
calendar-icon Last 4 years overview: 702 Published Papers | 25682 Citations
indexed-in-icon Indexed in: Scopus
last-updated-icon Last updated: 03/07/2020
Related journals
Insights
General info
Top papers
Popular templates
Get started guide
Why choose from SciSpace
FAQ

Related Journals

open access Open Access
recommended Recommended

PLOS

Quality:  
High
CiteRatio: 7.1
SJR: 1.99
SNIP: 1.774
open access Open Access

American Chemical Society

Quality:  
High
CiteRatio: 6.0
SJR: 1.324
SNIP: 1.029
open access Open Access
recommended Recommended

Oxford University Press

Quality:  
High
CiteRatio: 9.1
SJR: 2.124
SNIP: 1.646
open access Open Access

Frontiers Media

Quality:  
High
CiteRatio: 6.5
SJR: 1.812
SNIP: 1.485

Journal Performance & Insights

Impact Factor

CiteRatio

Determines the importance of a journal by taking a measure of frequency with which the average article in a journal has been cited in a particular year.

A measure of average citations received per peer-reviewed paper published in the journal.

24.446

11% from 2018

Impact factor for The Lancet Infectious Diseases from 2016 - 2019
Year Value
2019 24.446
2018 27.516
2017 25.148
2016 19.864
graph view Graph view
table view Table view

36.6

13% from 2019

CiteRatio for The Lancet Infectious Diseases from 2016 - 2020
Year Value
2020 36.6
2019 32.4
2018 31.9
2017 31.6
2016 32.9
graph view Graph view
table view Table view

insights Insights

  • Impact factor of this journal has decreased by 11% in last year.
  • This journal’s impact factor is in the top 10 percentile category.

insights Insights

  • CiteRatio of this journal has increased by 13% in last years.
  • This journal’s CiteRatio is in the top 10 percentile category.

SCImago Journal Rank (SJR)

Source Normalized Impact per Paper (SNIP)

Measures weighted citations received by the journal. Citation weighting depends on the categories and prestige of the citing journal.

Measures actual citations received relative to citations expected for the journal's category.

7.475

17% from 2019

SJR for The Lancet Infectious Diseases from 2016 - 2020
Year Value
2020 7.475
2019 9.04
2018 9.462
2017 9.963
2016 11.218
graph view Graph view
table view Table view

8.275

14% from 2019

SNIP for The Lancet Infectious Diseases from 2016 - 2020
Year Value
2020 8.275
2019 7.234
2018 6.29
2017 6.348
2016 6.688
graph view Graph view
table view Table view

insights Insights

  • SJR of this journal has decreased by 17% in last years.
  • This journal’s SJR is in the top 10 percentile category.

insights Insights

  • SNIP of this journal has increased by 14% in last years.
  • This journal’s SNIP is in the top 10 percentile category.
The Lancet Infectious Diseases

Guideline source: View

All company, product and service names used in this website are for identification purposes only. All product names, trademarks and registered trademarks are property of their respective owners.

Use of these names, trademarks and brands does not imply endorsement or affiliation. Disclaimer Notice

Elsevier

The Lancet Infectious Diseases

The aim of The Lancet Infectious Diseases is to publish interesting and informative research articles and reviews on any topic connected with infectious diseases and human health. Topics include, but are not limited to: Anti-infective therapy, Bacterial infections, Gastrointes...... Read More

Infectious Diseases

Medicine

i
Last updated on
03 Jul 2020
i
ISSN
1473-3099
i
Impact Factor
Maximum - 6.438
i
Acceptance Rate
7%
i
Open Access
Yes
i
Sherpa RoMEO Archiving Policy
Green faq
i
Plagiarism Check
Available via Turnitin
i
Endnote Style
Download Available
i
Bibliography Name
elsarticle-num
i
Citation Type
Numbered
[25]
i
Bibliography Example
G. E. Blonder, M. Tinkham, T. M. Klapwijk, Transition from metallic to tunneling regimes in superconducting microconstrictions: Excess current, charge imbalance, and supercurrent conversion, Phys. Rev. B 25 (7) (1982) 4515–4532. URL 10.1103/PhysRevB.25.4515

Top papers written in this journal

open accessOpen access Journal Article DOI: 10.1016/S1473-3099(20)30120-1
An interactive web-based dashboard to track COVID-19 in real time.
Ensheng Dong1, Hongru Du1, Lauren Gardner1

Abstract:

The outbreak of the 2019 novel coronavirus disease (COVID-19) has induced a considerable degree of fear, emotional stress and anxiety among individuals around t

Topics:

Dashboard (business) (62%)62% related to the paper, Web application (53%)53% related to the paper
8,336 Citations
Journal Article DOI: 10.1016/S1473-3099(15)00424-7
Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: A microbiological and molecular biological study

Abstract:

Summary Background Until now, polymyxin resistance has involved chromosomal mutations but has never been reported via horizontal gene transfer. During a routine surveillance project on antimicrobial resistance in commensal Escherichia coli from food animals in China, a major increase of colistin resistance was observed. When ... Summary Background Until now, polymyxin resistance has involved chromosomal mutations but has never been reported via horizontal gene transfer. During a routine surveillance project on antimicrobial resistance in commensal Escherichia coli from food animals in China, a major increase of colistin resistance was observed. When an E coli strain, SHP45, possessing colistin resistance that could be transferred to another strain, was isolated from a pig, we conducted further analysis of possible plasmid-mediated polymyxin resistance. Herein, we report the emergence of the first plasmid-mediated polymyxin resistance mechanism, MCR-1, in Enterobacteriaceae. Methods The mcr-1 gene in E coli strain SHP45 was identified by whole plasmid sequencing and subcloning. MCR-1 mechanistic studies were done with sequence comparisons, homology modelling, and electrospray ionisation mass spectrometry. The prevalence of mcr-1 was investigated in E coli and Klebsiella pneumoniae strains collected from five provinces between April, 2011, and November, 2014. The ability of MCR-1 to confer polymyxin resistance in vivo was examined in a murine thigh model. Findings Polymyxin resistance was shown to be singularly due to the plasmid-mediated mcr-1 gene. The plasmid carrying mcr-1 was mobilised to an E coli recipient at a frequency of 10 −1 to 10 −3 cells per recipient cell by conjugation, and maintained in K pneumoniae and Pseudomonas aeruginosa . In an in-vivo model, production of MCR-1 negated the efficacy of colistin. MCR-1 is a member of the phosphoethanolamine transferase enzyme family, with expression in E coli resulting in the addition of phosphoethanolamine to lipid A. We observed mcr-1 carriage in E coli isolates collected from 78 (15%) of 523 samples of raw meat and 166 (21%) of 804 animals during 2011–14, and 16 (1%) of 1322 samples from inpatients with infection. Interpretation The emergence of MCR-1 heralds the breach of the last group of antibiotics, polymyxins, by plasmid-mediated resistance. Although currently confined to China, MCR-1 is likely to emulate other global resistance mechanisms such as NDM-1. Our findings emphasise the urgent need for coordinated global action in the fight against pan-drug-resistant Gram-negative bacteria. Funding Ministry of Science and Technology of China, National Natural Science Foundation of China. read more read less

Topics:

MCR-1 (65%)65% related to the paper, Colistin (61%)61% related to the paper, Plasmid-mediated resistance (58%)58% related to the paper, Drug resistance (55%)55% related to the paper, Antibiotic resistance (54%)54% related to the paper
View PDF
3,647 Citations
open accessOpen access Journal Article DOI: 10.1016/S1473-3099(20)30243-7
Estimates of the severity of coronavirus disease 2019: a model-based analysis.

Abstract:

Background In the face of rapidly changing data, a range of case fatality ratio estimates for coronavirus disease 2019 (COVID-19) have been produced that differ substantially in magnitude. We aimed to provide robust estimates, accounting for censoring and ascertainment biases. Methods We collected individual-case data for pat... Background In the face of rapidly changing data, a range of case fatality ratio estimates for coronavirus disease 2019 (COVID-19) have been produced that differ substantially in magnitude. We aimed to provide robust estimates, accounting for censoring and ascertainment biases. Methods We collected individual-case data for patients who died from COVID-19 in Hubei, mainland China (reported by national and provincial health commissions to Feb 8, 2020), and for cases outside of mainland China (from government or ministry of health websites and media reports for 37 countries, as well as Hong Kong and Macau, until Feb 25, 2020). These individual-case data were used to estimate the time between onset of symptoms and outcome (death or discharge from hospital). We next obtained age-stratified estimates of the case fatality ratio by relating the aggregate distribution of cases to the observed cumulative deaths in China, assuming a constant attack rate by age and adjusting for demography and age-based and location-based under-ascertainment. We also estimated the case fatality ratio from individual line-list data on 1334 cases identified outside of mainland China. Using data on the prevalence of PCR-confirmed cases in international residents repatriated from China, we obtained age-stratified estimates of the infection fatality ratio. Furthermore, data on age-stratified severity in a subset of 3665 cases from China were used to estimate the proportion of infected individuals who are likely to require hospitalisation. Findings Using data on 24 deaths that occurred in mainland China and 165 recoveries outside of China, we estimated the mean duration from onset of symptoms to death to be 17·8 days (95% credible interval [CrI] 16·9-19·2) and to hospital discharge to be 24·7 days (22·9-28·1). In all laboratory confirmed and clinically diagnosed cases from mainland China (n=70 117), we estimated a crude case fatality ratio (adjusted for censoring) of 3·67% (95% CrI 3·56-3·80). However, after further adjusting for demography and under-ascertainment, we obtained a best estimate of the case fatality ratio in China of 1·38% (1·23-1·53), with substantially higher ratios in older age groups (0·32% [0·27-0·38] in those aged Interpretation These early estimates give an indication of the fatality ratio across the spectrum of COVID-19 disease and show a strong age gradient in risk of death. Funding UK Medical Research Council. read more read less

Topics:

Case fatality rate (66%)66% related to the paper, Mainland China (51%)51% related to the paper
3,271 Citations
Journal Article DOI: 10.1016/S1473-3099(17)30753-3
Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis.
Evelina Tacconelli1, Elena Carrara1, Alessia Savoldi1, Stéphan Juergen Harbarth2, Marc Mendelson3, Dominique L Monnet4, Céline Pulcini, Gunnar Kahlmeter, Jan Kluytmans5, Yehuda Carmeli6, Marc Ouellette7, Kevin Outterson8, Jean B. Patel9, Marco Cavaleri10, Edward Cox11, Christopher R. Houchens12, M Lindsay Grayson13, Paul Hansen14, Nalini Singh15, Ursula Theuretzbacher, Nicola Magrini2, Aaron O. Aboderin, Seif Al-Abri, Nordiah Awang Jalil, Nur Benzonana, Sanjay Bhattacharya, Adrian Brink, Francesco Robert Burkert, Otto Cars, Giuseppe Cornaglia, Oliver J. Dyar, Alexander W. Friedrich, Ana Cristina Gales, Sumanth Gandra, Christian G. Giske, Debra A. Goff, Herman Goossens, Thomas Gottlieb, Manuel Guzman Blanco, Waleria Hryniewicz, Deepthi Kattula, Timothy Jinks, Souha S. Kanj, Lawrence Kerr, Marie-Paule Kieny, Yang Soo Kim, Roman S. Kozlov, Jaime Labarca, Ramanan Laxminarayan, Karin Leder, Leonard Leibovici, Gabriel Levy-Hara, Jasper Littman, Surbhi Malhotra-Kumar, Vikas Manchanda, Lorenzo Moja, Babacar Ndoye, Angelo Pan, David L. Paterson, Mical Paul, Haibo Qiu, Pilar Ramon-Pardo, Jesús Rodríguez-Baño, Maurizio Sanguinetti, Sharmila Sengupta, Mike Sharland, Massinissa Si-Mehand, Lynn L. Silver, Wonkeung Song, Martin Steinbakk, Jens Thomsen, Guy E. Thwaites, Jos W. M. van der Meer, Nguyen Van Kinh, Silvio Vega, Maria Virginia Villegas, Agnes Wechsler-Fördös, Heiman F. L. Wertheim, Evelyn Wesangula, Neil Woodford, Fidan O Yilmaz, Anna Zorzet

Abstract:

Summary Background The spread of antibiotic-resistant bacteria poses a substantial threat to morbidity and mortality worldwide. Due to its large public health and societal implications, multidrug-resistant tuberculosis has been long regarded by WHO as a global priority for investment in new drugs. In 2016, WHO was requested b... Summary Background The spread of antibiotic-resistant bacteria poses a substantial threat to morbidity and mortality worldwide. Due to its large public health and societal implications, multidrug-resistant tuberculosis has been long regarded by WHO as a global priority for investment in new drugs. In 2016, WHO was requested by member states to create a priority list of other antibiotic-resistant bacteria to support research and development of effective drugs. Methods We used a multicriteria decision analysis method to prioritise antibiotic-resistant bacteria; this method involved the identification of relevant criteria to assess priority against which each antibiotic-resistant bacterium was rated. The final priority ranking of the antibiotic-resistant bacteria was established after a preference-based survey was used to obtain expert weighting of criteria. Findings We selected 20 bacterial species with 25 patterns of acquired resistance and ten criteria to assess priority: mortality, health-care burden, community burden, prevalence of resistance, 10-year trend of resistance, transmissibility, preventability in the community setting, preventability in the health-care setting, treatability, and pipeline. We stratified the priority list into three tiers (critical, high, and medium priority), using the 33rd percentile of the bacterium's total scores as the cutoff. Critical-priority bacteria included carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa , and carbapenem-resistant and third-generation cephalosporin-resistant Enterobacteriaceae. The highest ranked Gram-positive bacteria (high priority) were vancomycin-resistant Enterococcus faecium and meticillin-resistant Staphylococcus aureus . Of the bacteria typically responsible for community-acquired infections, clarithromycin-resistant Helicobacter pylori , and fluoroquinolone-resistant Campylobacter spp, Neisseria gonorrhoeae , and Salmonella typhi were included in the high-priority tier. Interpretation Future development strategies should focus on antibiotics that are active against multidrug-resistant tuberculosis and Gram-negative bacteria. The global strategy should include antibiotic-resistant bacteria responsible for community-acquired infections such as Salmonella spp, Campylobacter spp, N gonorrhoeae , and H pylori . Funding World Health Organization. read more read less

Topics:

Antibiotic resistance (54%)54% related to the paper
3,184 Citations
open accessOpen access Journal Article DOI: 10.1016/S1473-3099(13)70318-9
Antibiotic resistance—the need for global solutions

Abstract:

The causes of antibiotic resistance are complex and include human behaviour at many levels of society; the consequences affect everybody in the world. Similarities with climate change are evident. Many efforts have been made to describe the many different facets of antibiotic resistance and the interventions needed to meet th... The causes of antibiotic resistance are complex and include human behaviour at many levels of society; the consequences affect everybody in the world. Similarities with climate change are evident. Many efforts have been made to describe the many different facets of antibiotic resistance and the interventions needed to meet the challenge. However, coordinated action is largely absent, especially at the political level, both nationally and internationally. Antibiotics paved the way for unprecedented medical and societal developments, and are today indispensible in all health systems. Achievements in modern medicine, such as major surgery, organ transplantation, treatment of preterm babies, and cancer chemotherapy, which we today take for granted, would not be possible without access to effective treatment for bacterial infections. Within just a few years, we might be faced with dire setbacks, medically, socially, and economically, unless real and unprecedented global coordinated actions are immediately taken. Here, we describe the global situation of antibiotic resistance, its major causes and consequences, and identify key areas in which action is urgently needed. read more read less

Topics:

Antibiotic misuse (55%)55% related to the paper, Modern medicine (52%)52% related to the paper
View PDF
3,181 Citations
Author Pic

SciSpace is a very innovative solution to the formatting problem and existing providers, such as Mendeley or Word did not really evolve in recent years.

- Andreas Frutiger, Researcher, ETH Zurich, Institute for Biomedical Engineering

Get MS-Word and LaTeX output to any Journal within seconds
1
Choose a template
Select a template from a library of 40,000+ templates
2
Import a MS-Word file or start fresh
It takes only few seconds to import
3
View and edit your final output
SciSpace will automatically format your output to meet journal guidelines
4
Submit directly or Download
Submit to journal directly or Download in PDF, MS Word or LaTeX

(Before submission check for plagiarism via Turnitin)

clock Less than 3 minutes

What to expect from SciSpace?

Speed and accuracy over MS Word

''

With SciSpace, you do not need a word template for The Lancet Infectious Diseases.

It automatically formats your research paper to Elsevier formatting guidelines and citation style.

You can download a submission ready research paper in pdf, LaTeX and docx formats.

Time comparison

Time taken to format a paper and Compliance with guidelines

Plagiarism Reports via Turnitin

SciSpace has partnered with Turnitin, the leading provider of Plagiarism Check software.

Using this service, researchers can compare submissions against more than 170 million scholarly articles, a database of 70+ billion current and archived web pages. How Turnitin Integration works?

Turnitin Stats
Publisher Logos

Freedom from formatting guidelines

One editor, 100K journal formats – world's largest collection of journal templates

With such a huge verified library, what you need is already there.

publisher-logos

Easy support from all your favorite tools

The Lancet Infectious Diseases format uses elsarticle-num citation style.

Automatically format and order your citations and bibliography in a click.

SciSpace allows imports from all reference managers like Mendeley, Zotero, Endnote, Google Scholar etc.

Frequently asked questions

1. Can I write The Lancet Infectious Diseases in LaTeX?

Absolutely not! Our tool has been designed to help you focus on writing. You can write your entire paper as per the The Lancet Infectious Diseases guidelines and auto format it.

2. Do you follow the The Lancet Infectious Diseases guidelines?

Yes, the template is compliant with the The Lancet Infectious Diseases guidelines. Our experts at SciSpace ensure that. If there are any changes to the journal's guidelines, we'll change our algorithm accordingly.

3. Can I cite my article in multiple styles in The Lancet Infectious Diseases?

Of course! We support all the top citation styles, such as APA style, MLA style, Vancouver style, Harvard style, and Chicago style. For example, when you write your paper and hit autoformat, our system will automatically update your article as per the The Lancet Infectious Diseases citation style.

4. Can I use the The Lancet Infectious Diseases templates for free?

Sign up for our free trial, and you'll be able to use all our features for seven days. You'll see how helpful they are and how inexpensive they are compared to other options, Especially for The Lancet Infectious Diseases.

5. Can I use a manuscript in The Lancet Infectious Diseases that I have written in MS Word?

Yes. You can choose the right template, copy-paste the contents from the word document, and click on auto-format. Once you're done, you'll have a publish-ready paper The Lancet Infectious Diseases that you can download at the end.

6. How long does it usually take you to format my papers in The Lancet Infectious Diseases?

It only takes a matter of seconds to edit your manuscript. Besides that, our intuitive editor saves you from writing and formatting it in The Lancet Infectious Diseases.

7. Where can I find the template for the The Lancet Infectious Diseases?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per The Lancet Infectious Diseases's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

8. Can I reformat my paper to fit the The Lancet Infectious Diseases's guidelines?

Of course! You can do this using our intuitive editor. It's very easy. If you need help, our support team is always ready to assist you.

9. The Lancet Infectious Diseases an online tool or is there a desktop version?

SciSpace's The Lancet Infectious Diseases is currently available as an online tool. We're developing a desktop version, too. You can request (or upvote) any features that you think would be helpful for you and other researchers in the "feature request" section of your account once you've signed up with us.

10. I cannot find my template in your gallery. Can you create it for me like The Lancet Infectious Diseases?

Sure. You can request any template and we'll have it setup within a few days. You can find the request box in Journal Gallery on the right side bar under the heading, "Couldn't find the format you were looking for like The Lancet Infectious Diseases?”

11. What is the output that I would get after using The Lancet Infectious Diseases?

After writing your paper autoformatting in The Lancet Infectious Diseases, you can download it in multiple formats, viz., PDF, Docx, and LaTeX.

12. Is The Lancet Infectious Diseases's impact factor high enough that I should try publishing my article there?

To be honest, the answer is no. The impact factor is one of the many elements that determine the quality of a journal. Few of these factors include review board, rejection rates, frequency of inclusion in indexes, and Eigenfactor. You need to assess all these factors before you make your final call.

13. What is Sherpa RoMEO Archiving Policy for The Lancet Infectious Diseases?

SHERPA/RoMEO Database

We extracted this data from Sherpa Romeo to help researchers understand the access level of this journal in accordance with the Sherpa Romeo Archiving Policy for The Lancet Infectious Diseases. The table below indicates the level of access a journal has as per Sherpa Romeo's archiving policy.

RoMEO Colour Archiving policy
Green Can archive pre-print and post-print or publisher's version/PDF
Blue Can archive post-print (ie final draft post-refereeing) or publisher's version/PDF
Yellow Can archive pre-print (ie pre-refereeing)
White Archiving not formally supported
FYI:
  1. Pre-prints as being the version of the paper before peer review and
  2. Post-prints as being the version of the paper after peer-review, with revisions having been made.

14. What are the most common citation types In The Lancet Infectious Diseases?

The 5 most common citation types in order of usage for The Lancet Infectious Diseases are:.

S. No. Citation Style Type
1. Author Year
2. Numbered
3. Numbered (Superscripted)
4. Author Year (Cited Pages)
5. Footnote

15. How do I submit my article to the The Lancet Infectious Diseases?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per The Lancet Infectious Diseases's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

16. Can I download The Lancet Infectious Diseases in Endnote format?

Yes, SciSpace provides this functionality. After signing up, you would need to import your existing references from Word or Bib file to SciSpace. Then SciSpace would allow you to download your references in The Lancet Infectious Diseases Endnote style according to Elsevier guidelines.

Fast and reliable,
built for complaince.

Instant formatting to 100% publisher guidelines on - SciSpace.

Available only on desktops 🖥

No word template required

Typset automatically formats your research paper to The Lancet Infectious Diseases formatting guidelines and citation style.

Verifed journal formats

One editor, 100K journal formats.
With the largest collection of verified journal formats, what you need is already there.

Trusted by academicians

I spent hours with MS word for reformatting. It was frustrating - plain and simple. With SciSpace, I can draft my manuscripts and once it is finished I can just submit. In case, I have to submit to another journal it is really just a button click instead of an afternoon of reformatting.

Andreas Frutiger
Researcher & Ex MS Word user
Use this template